Purine Pharma, LLC Enters into Licensing Agreement for Marketing And Distributing Nutraceutical & C

NEW YORK - Oct. 27, 2014 - PRLog -- EastGate Acquisitions Corp (ESAQ) announced that with Purine Pharma, LLC, the two companies have entered into a licensing agreement whereby Purine will manufacture, distribute, and market ESAQ’s nutraceutical line of products under a private label.  This agreement is seen as incredibly beneficial to both companies in that ESAQ can now progress with the company’s business plan to license its entire suite of products while Purine can expand the reach into international markets under this new private label branding. The ESAQ nutraceutical product line can be found at www.nano-essentials.com.

"Our agreement with Purine Pharma solidifies the company's progression to commercialization" says Anna Gluskin , EastGate's CEO.  "Opening up the distribution channels for our innovative product line utilizing our sub-micron platform technology, this will reinforce our technology, expand our product line and  build a revenue stream for the company."

Under the agreement, EastGate also has the option to utilize Purine Pharma as a contract manufacturer for ESAQ’s own brand name labels specific to the EastGate customer base.  The added benefit outside of international distribution is that Purine also has over 200 products in its portfolio including several health focused items that include analgesic, topical and vitamin supplements, as well as cold & allergy medicine.

EastGate’s model is based on a multi-tiered approach that includes development of novel pharma-based products and innovative dietary supplements.  Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules.  The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes.

ESAQ’s natural dietary supplements include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions.  EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development.  We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate's approach will be most beneficial for patient care.

The global nutraceutical ingredients market is forecast to record yearly growth in excess of 7% to reach almost $24 billion in 2015, according to research from Freedonia (http://www.reportlinker.com/p0703616-summary/World-Nutrac...). The greatest growth will come from ingredients with clinically confirmed health benefits that can be used in a wide rang of dietary supplements, drinks, foods, and nutritional preparations for children and adults. Market growth across developing nations is expected to be faster in terms of consumption and production compared with developed nations.

Furthermore the study shows that the nutrients market (which represents the market segment with the highest sales within the nutraceutical ingredients industry) growth is expected to exceed 6.5% to reach almost $10.5 billion in 2015. Proteins are expected to record the fastest gains due to food and beverage manufacturers opting to use high value-added nutritional preparations in their products. Demand for functional additives and fiber nutrients will be fuelled by clinical evidence pointing to the health benefits of these ingredients.  Based on the overall scope of what ESAQ has already done with its sublingual tablet to help treat diabetes, this should bode very well for the company based on the overall makeup of the ingredients in this revolutionary tablet.

For more information on Eastgate Acquisitions and other emerging companies in the medical and nutraceuticals industry, sign up for your free report at http://wwww.investornewssource.com

Disclaimer can be found at http://www.investornewssource.com